惠大生物 ABOUT US
北京惠大生物科技有限公司坐落于北京亦庄经济开发区，拥有1880平米实验室和办公室。公司从美国马里兰大学引进的“IHV-DC”技术突破了细胞免疫抗癌技术的瓶颈，极有可能为人类彻底攻克癌症打开希望之门；世界著名病毒学家、生物学家Robert Gallo对技术评价说：这是一项伟大的发现，有划时代意义，它有可能开启治疗癌症和病毒的新篇章。
公司将基于IHV-DC技术逐步以下方面开展研发和产业化经营活动：（一）肿瘤过继性细胞免疫治疗：逐步开展针对实体肿瘤的临床和新药申报。（二）病毒感染性疾病治疗；（三）肿瘤新抗原个性化疗法，基于永生化DC细胞的抗癌疫苗设计应用，预防癌症扩散和复发。
目前，惠大生物与中国人民解放军总医院（301医院）正在开展IHV-DC技术治疗非小细胞肺癌的临床实验。
Situated in the Beijing Economic-Technological Development Area, Huida Biotechnology is an enterprise with a registered capital of RMB350 million. This enterprise engages in the research and exploitation of cellular immunotherapy. Cellular immunotherapy kills tumors in a patient through the “transformation” of the immunocytes into an “immunocyte corps” and transferring them into the patient’s body in order to prevent the transfer or recrudescence of tumors, prolong survival time and improve the quality of life of the patient. In 2013, cellular immunotherapy was selected to be the “Breakthrough of the Year” by Science. From then on, cellular immunotherapy has drawn extensive attention in the academic world.
The Company has engaged in strategic cooperation with the Institute of Human Virology of the School of Medicine, University of Maryland, with the goal to industrialize the immunotherapy in China.
The Company has engaged in strategic cooperation with the Institute of Human Virology of the School of Medicine, University of Maryland, with the goal to industrialize the immunotherapy in China.
The IHV of the University of Maryland is one of the foremost authorities on HIV basic research, R&D of HIV drugs and vaccines, animal experiments, as well as clinical diagnosis and treatment in the world; and especially on cellular research. Co-founded by Robert Gallo, MD, director of the of the IHV, and IHV’s Chinese professors and directors, Huida Biotechnology has committed itself to offering both safe and effective cellular immunotherapy-based solutions to Chinese patients.
鲍一明博士，中国科学院北京基因组研究所，生命与健康大数据中心主任，博士生导师。
王贵强教授，北大医院教授，匹兹堡大学Research Associate, 从事T淋巴细胞凋亡的分子机制和DC过继免疫治疗的基础和临床研究。
杨福全，中国科学院生物物理研究所研究员、博士生导师，质谱首席科学家。
郑撼球，清华大学医学院 研究员；普林斯顿大学分子生物学系博士后；奥尔巴尼医学院细胞学和癌症学中心博士。
王盛典，分子免疫学家，中国科学院生物物理研究所研究员，博士生导师，中国科学院“百人计划”获得者。
马洁博士，北京医院生物治疗中心主任,中国医学科学院肿瘤医院分子肿瘤学国家重点实验室研究员。 
邵永平教授，西安交大前沿科技研究院负责人，毕业于纽约州立大学Albany分校，研究方向为细胞生物学和肿瘤生物学。
都培双教授，中国科学院感染与免疫研究中心副主任。